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This paper swmnarizes some important aspects of 
atherosclerotic regression. The morphology of the normal arterial 
wall and its composition are described briefly. Atherogenesis and 
the histopathology of atherosclerotic lesions are discussed in 
detai 1 including observations of structures 1 ike foam cells it 
relationship with oxidized 1 ow density 1 ipoprotein. Also some 
aspects about the physicochemical characteristics of lipids are 
described and their relationship with the arterial intima. The 
metabolism of cholesterol and the lipoproteins are discussed and 
their effect on the emergence of atherosclerotic lesions. An 
anatomical definition of the process of atherosclerotic regression 
is given and the steps of the atherosclerotic regression process 
are briefly described. Lastly, some hypocholesterolemic regimens, 
namely diets and drugs, are evaluated with respect to evidence from 
studies in animals and man of their efficacy in inducing 
atherosclerotic regression. 
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Introduction 
Atherosclerosis currently represents one of the 
subjects that has stimulated the most intensive research in 
medicine. Coronary atherosclerosis is responsible for more 
deaths each year than any other disease (including deaths 
from all types of cancers combined). The United States 
spends over $60 billion each year in direct and indirect 
health care expenses (Levy 1986). 
For a number of years, evidence has been accumulating 
to indicate that elevated plasma cholesterol levels are the 
cause for the emergence of coronary atherosclerosis 
(Anderson et al. 1987). Recent investigations in the 
development of hypocholesterolemic regimens has resulted in 
a variety of chol estero! 1 owe ring diets and drugs. The 
effects of such regimens have also brought forth 
interesting data regarding the state of the atherosclerotic 
plaque or atheroma. It has been sugg~sted that by lowering 
plasma cholesterol levels lipid trapped within the atheroma 
can be mobilized enhancing the rate of cholesterol efflux 
from the atherosclerotic plaque (Small 1988). The fact that 
there is a dynamic and constant exchange of lipid between 
the blood and the endothelium of the arteries demonstrates 
an equilibrium between the two mediums. This equilibrium 
could be altered in favor of increased outward flow of 
lipid from the affected regions where atherosclerotic 
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lesions are present. 
There is still some controversy as to whether 
atherosclerotic lesions can be made to reqress and to what 
extent this may occur (Clarkson et al. 1981}. A series of 
arterial anqioqraphic studies, histoloqic and anatomical 
observations in both animal models and human subjects have 
brouqht forth descriptive data demonstratinq the 
atherosclerotic reqression. 
The followinq paper will examine the histopatholoqy 
that leads to the formation of an atherosclerotic plaque in 
relation to the metabolic and physicochemical 
characteristics of cholesterol.This paper also examines 
some of the hypocholesterolemic reqimens from which 
reqression of atherosclerotic lesions has been demonstrated 
in experimental animals and human subjects. 
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Atherosclerosis Defined 
Arteriosclerosis is the generic term used to describe 
different patterns of vascular disease which cause 
hardening or thickening of the arteries as well as a loss 
in their compliance and elasticity. The most characteristic 
pattern is atherosclerosis. It is a process that develops 
in the intima of the blood vessels leading to the formation 
of a series of space-occupying lesions composed of 
accumulations of fatty and fibrous material, which 
compromise the patency of the vessel 1 umen and the 
anatomical integrity of the media. In 1963, Pickering 
supported the property and usefulness of the term 
atherosclerosis, stemming from the greek "athera" which 
means "porridge-! ike hardness", as a correct terminology 
for such an idiopathy (Robbins and Kumar 1987). 
Atherosclerosis is the principal cause of death in 
more than 50\ of individuals in developed countries. And 
almost all of their population has some degree of 
atherosclerosis (Lickoff 1972). "No disease in the United 
States is responsible for more deaths, has stimulated more 
research, and has engendered more controversy about 
approaches to its control than atherosclerosis" (Robbins 
and Kumar 1987). 
Atherosclerosis can begin early in life and progresses 
in stages. Shortly after one year of life in humans, lipid 
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deposits, often referred to as fatty streaks, appear in the 
intima of the aorta, particularly around the cusps of the 
heart valves. These deposits usually disappear but by the 
end of the first decade these are seen again and continue 
to accumulate for the rest of the individual's life (King 
et al. 1983). Fatty streaks are considered by some 
investigators as tissue expression of 'shear stresses' and 
perhaps as an initial and reversible stage of 
atherogenesis. 
The second stage of the atherosclerotic process is 
characterized by the formation of a fibrous lesion called 
the atherosclerotic plaque. This is a "firm mound-like 
lesion" containing lipids, principally cholesterol, in the 
intimal and medial layer of the vasculature and found 
within myoendothelial cells and macrophages and as free 
cholesterol. Then, macrophages combine with calcium to form 
a superimposed cellular accumulation that leads to the 
worsening of the atherosclerotic plaque and reduction of 
the diameter of the 1 umen of the vessel (Boucek et al. 
1987). 
Progression of the atherosclerotic lesion usually 
results from increased deposition of lipid associated with 
calcium depositions. The deposition of calcium gives a 
hardened character to these lesions. The thickened intimal 
plaque is infiltrated by cells known as monocytes which 
later become macrophages as they penetrate the lesion. Some 
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smooth muscle cells "also proliferate and become surrounded 
by interstitial fibrosis and hyalinization as well as 
cholesterol crystals" ( King et al. 1983). 
Although vast information about the atherosclerotic 
process has been elucidated, the present knowledge of 
mechanisms involved in atherogenesis are still largely 
unknown. Current experimental data and further 
investigation may clear some uncertainties about the 
disease. 
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Morphology of the Arterial Wall 
"The arteries are dynamic structures capable of 
adapting to changes quickly as they are inf 1 uenced by 
certain hemodynamic variables of blood flow. These are 
divided into three main categories: the elastic arteries, 
the muscular arteries, and the arterioles" (Ross and Reith 
1985). The latter are the arteries responsible for 
providing resistance to flow before blood arrives to the 
capi 11 aries. All three types of arteries share common 
morphological structures as they are composed of three 
layers, namely the tunica intima, the tunica media, and the 
tunica adventitia. 
The tunica intima is the closest layer to the vascular 
lumen. It is composed of a network of endothelial cells and 
related connective tissue which together form the vessel's 
endothelium. The intima of the elastic arteries, although 
it varies with distance from the heart, comprises about 25\ 
of the total thickness of the artery. These flattened 
simple squamous epithelial cells rest on a basement 
membrane, underneath which there is a layer of 
inconspicuous elastic material known as the internal 
elastic membrane. 
The endothelial cells are held together by essentially 
two types of junctions: zonula occludens (tight junctions), 
and a nexus or gap junction. The zonula occludens, as seen 
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through electron microscopy and freeze fracture, is 
visualized as interlacing ridges around this area. It is 
not a patch but rather a belt or band that goes around the 
endothelial cells. 
The nexus or gap junction is made of a 201 space or 
"gap" between endothelial cells. Functionally, they serve 
to attach epithelial cells together and for rapid cell-to-
cell communication. Both the tight junction and the gap 
junction not only hold the cells together but also prevent 
the diffusion of substances between endothelial cells, 
acting like a chemical seal between environments. Hence, 
transport of some substances must occur through vesicles 
across the endothelial membrane through the process known 
as endocytosis. This phenomenon shall prove of great 
relevance in our discussion of cholesterol diffusion across 
the endothelium. In the larger arteries, besides possessing 
an internal elastic membrane, the subendothelium contains 
collagen and elastic fibers or ground substance which are 
manufactured by the main cell type in this layer, the 
smooth muscle cell. After the arterial lesion is formed 
macrophages are also present in the endothelium, which 
together with the smooth muscle cells, share a part in the 
pathology of cholesterol accumulation in the intima. 
The tunica media is the thickest of the three arterial 
layers. The tunica media is very rich in elastic fibers 
which are arranged in bundles or concentric lamellae with 
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extracellular matrix and ground substance scattered around 
it. The medial layer is also referred to as the muscular 
layer because it is the section in which smooth muscle 
cells are more abundant. It is worth noting that due to the 
absence of fibroblast in the intima and media, the smooth 
muscle cells are responsible for the production of collagen 
and elastic fibers. This function of the smooth muscle 
cells is exacerbated in atherosclerosis. 
The tunica adventitia is the outermost layer composed 
of connective tissue which becomes continuous with the 
surrounding connective tissues forming the stroma of the 
organ. In the elastic arteries, the tunica adventitia 
comprises only 50\ that of the thickness of the tunica 
media. At the boundary of the tunica media and the tunica 
adventitia, elastic fibers become interlaced to form the 
external elastic membrane. The dynamic structure of the 
elastic membrane is due mainly to the high concentration of 
collagenous fibers which expand during systole and then 
recoil to their original state providing a pulse or wave of 
blood transit through the arteries. In contrast to the 
cellular composition of the tunica media and most certainly 
the tunica intima, the tunica adventitia is composed mainly 
of fibroblast and macrophages. Since the tunica adventitia 
is furthest from the main circulation, in major arteries 
diffusion of oxygen and nutrients from the lumen does not 
meet the need of the tissue. Hence, a separate set of blood 
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vessels known as the vasa vasorum, provides the necessary 
nutrients and the removal of metabolites for the proper 
maintenance of the outer 1 ayers of the arterial wall. 
However, such structure is not found in the coronary 
arteries. 
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Histopathology and Atherosclerosis 
In the last few years atherosclerosis has been 
approached as an ailment whose etiology is based on the 
process of lipid or fat accumulation. This understanding 
has led to the development of useful and valuable means to 
treat this ailment. 
As mentioned previously, atherosclerosis is a process 
that starts early in life and continues to develop 
throughout life. Researchers have pointed to an increasing 
rigidity of the major arteries, 1 ike the aorta and the 
coronary arteries, due to a decrease in the 
elastin/collagen ratio (Finch & Hayflick 1977). "This 
rigidity results in a progressive decrease of the capacity 
of the aorta to dilate and accommodate the systolic volume, 
and a decrease of the elastic recoil of the aorta, which 
helps push the expelled blood volume toward the periphery 
during diastole" (Gotto & Paoletti 1986). This increase in 
vessel rigidity can lead to progressive fragmentation of 
the internal elastic membrane and increasing collagen 
deposition in the lacerated endothelium. 
The concept of the endothelium as a barrier of 
"selective permeability" has been elucidated from many 
studies, especially from those performed by Schwartz and 
colleagues, who experimented on problems with the 
transendothel ial passage of macromolecules in the 1 arge 
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arteries. (Schwartz, Gerrity and Lewis 1977). Their data 
suggests that the permeability of the endothelium to 
macromolecules like lipids, may show significant regional 
variation and that this variation is mediated through 
hemodynamic factors. Additionally, "the areas of greatest 
permeability [to lipids] like the coronary arteries, aorta 
and femoral arteries appear to be most at risk for the 
subsequent development of an atherosclerotic lesion" (Woolf 
1982). 
Morphology of the development of an atherosclerotic 
lesion is mainly characterized by three stages: the fatty 
streak, the intermediate lesion or fibrous plaque, and the 
complicated or gruel plaque. 
Although the visibility of a very first lesion on the 
endothelial wall has been somewhat controversial among 
histopathologists, "the general consensus has been to 
consider the fatty dot or streak as the best recognizable 
structure leading the process of atherogenesis. The fatty 
streaks are found mainly throughout the large arteries and 
are routinely encountered in infants and young children" 
(Small 1988). These generally cause no or minimal 
obstruction of the vascular lumen and often show no 
clinical symptoms as they go unnoticed. Schwartz (1967) 
noticed that the incidence of fatty streaks in 43 out of 
100 infants (between the ages of 1-12 months), that were 
coming to necropsy, were mostly localized to the aortic 
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valve, the ductus scar and distal to the ostia of the 
intercostal arteries. During puberty, fatty streaks appear 
mostly in the left coronary arteries like round yellowish 
patches minimally elevated around the endothelium averaging 
2 by 10mm in size. Histologically, all of these lesions 
contain cells that have considerable 1 ipid accumulation 
known as "foam cells". These are derived from monocytes 
that wander in the circulation and smooth muscle cells that 
are present in the media of the arterial wall which invade 
the intima in the case of excess lipid deposition (Robbins 
and Kumar 1987). Foam cells which shall be discussed in 
detail later on, are overloaded with lipid droplet 
occlusions and are visualized as regional elevations of the 
intima. 
In Pathol oqy of Atherosclerosis, Woolf describes, form 
the work of Mitchell and Schwartz (1965), the distribution 
pattern of these fatty streaks in adults. He mentions that 
"the streaks were distributed in a fan-shaped patte'rn made 
up of discrete confluent streaks which distally become 
concentrated on the posterior aspect of the aorta". Again, 
due to the hemodynamic of blood flow in the arteries, a 
pattern emerges from the intima of the affected vessels, 
giving an overall structure to this atherosclerotic lesion. 
Lipid found in the fatty streaks is mainly 
concentrated in the endothelial and smooth muscle cells. 
The lipid accumulated in these lesions is similar in 
12 
appearance to the uniform infi 1 trations of 1 ipid found 
normally in clear vacuoles. Any difference in the 
histological observations of accumulated lipid in the fatty 
streaks arise as a result of differences in the chemical 
composition of the lipids present in this lesion. Although 
most of the lipid hereby described is present principally 
in these cells, in patients with hyperlipoproteinemic 
disorders there can also be accumulation of lipid in the 
extracellular spaces {Woolf 1982). 
The role of the fatty streak as a precursor of 
atherosclerosis has been an issue of considerable 
discussion. The fatty streak differs from atherosclerotic 
plaque in that most of the lipid is intracellular and very 
little lipid in the extracellular matrix. The immediate 
tissue about the accumulated lipid is not necrotic. Thus it 
is suggested that due to their minimal effect on the 
arterial wall, the fatty streak lesions are readily 
reversible (Robbins and Kumar 1987). 
Small (1984) suggests that the physicochemical nature 
of lipids is what makes their accumulation characteristic. 
The three different densities of the lipid accumulated in 
these lesions can be represented in a graph which accounts 
for each one of these lipids at its axes: a cholesterol 
axis, a phospholipid axis, and a cholesterol-ester axis. 
According to the concentration of each lipid in the 
specific atherosclerotic lesion stage (that is, fatty 
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streak, intermediate plaque and gruel plaque) one can find 
how many lipid phases there are in a specific 
atherosclerotic lesion stage as plotted in the triangular 
coordinate with the defined axes. Ordinary fatty streaks 
consists primarily of two lipids, that is phospholipid and 
cholesterol. The mixture of these two lipids is considered 
to lie in what Small refers to as zone III because these 
two lipids separate into a phase of cholesterol (zone II) 
that floats in water, and a phospholipid or "lamellar 
liquid-crystalline phase" (zone I) which when centrifuged 
appears at the bottom of the phase separation. This lipid 
mixture is characteristic of a fatty streak where 
cholesterol ester droplets can be identified (Small 1977). 
The second stage of atherogenesis is the formation of 
the fibrous or intermediate plaque. Whereas the fatty 
streak is a yellow fan-like protrusion into the arterial 
lumen, the fibrous plaque is white and clearly invades the 
vessel lumen. The lesion contains cholesterol esters which 
accumulate in the smooth muscle cells in the intima of the 
arteries. Woolf comments that the fibrous or intermediate 
plaque are very much elevated(as it is filled with lipid 
deposits) above the surface of the non-affected intimal 
layer and that even if the media shows no loss of 
thickness, the edematous intima may be greater or equal in 
thickness to the underlying media and intima. Endothelial 
cells and the extracellular matrix, also intruded with 
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lipid, form the fibrous plaque that covers a deeper deposit 
of cell debris, free extracellular lipid and other plasma-
derived constituents. Stary ( 1987) mentions that after 
staining with Sudan IV, he found that the elevations had 
a pink periphery. "The coloration reflected the microscopic 
observation of superficially located foam cells at the 
thinner periphery, while the thick midportion remained 
unstained because both intracellular and extracellular 
lipid were submerged well below the surface of the fibrous 
plaque". Stary often referred to the intermediate plaque as 
a "pre-atheroma". 
In order for the fibrous plaque to come about, 
invasion of the medial layer of the vessel wall does not 
need to be involved. However if it does happen it could 
result in the hypertrophy of the smooth muscle cells lying 
underneath the affected intimal 
tendency for these plaques to be 
region. There is a 
located at specific 
vessels. It is worth noting that "the predilection' of the 
emergent areas [for the formation of atheroclerostic 
plaques] of the left anterior descending artery (LAD) and 
the circumflex artery (CxA) and the left coronary artery 
( LCA), in particular, represent the sites in the heart 
where the greatest extent and severity of involvement is 
found for the generation of the fibrous plaques" (Boucek et 
al. 1984). Free fatty acids that accumulate in the fibrous 
lesion combine with calcium to form "calcium soaps" which 
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lay on the arterial wall contributing to what is commonly 
known in atherosclerosis as hardening of the arteries. Upon 
hypertrophy of the immediate underlying myointimal cells, 
collagen is overproduced and the internal elastic membranes 
is disrupted with the reduction of the elastic fibrils in 
the media (King et al. 1983). Intermediate plaques are most 
commonly found lying in the same plane as the intimal 
surface resulting in lesion formation and decreased elastic 
content of the intima (Robbins and Kumar 1987). Although 
the transition between the fatty streak and the 
intermediate plaque have not been well investigated, 
increases in cholesterol accumulation renders the 
cholesterol esterifying enzyme, acyl cholesterol CoA: 
acyl transferase (ACAT), insufficient in activity to the 
point where it is unable to esterify fat, thereby leading 
to further accumulation of unesterified cholesterol in the 
atherosclerotic plaque. Experiments perfomed in rat 
hepatocytes have shown to contain cholesterol d'roplets 
representing the intermediate plaque (Adams 1973; Bleich 
1977). 
The third stage of atherosclerosis is the formation of 
the complicated or gruel plaque. The complicated plaque 
comes forth as a result of worsening of the fibrous plaque 
as it becomes calcified due to the deposition of calcium 
soaps, degeneration of the smooth muscle, ulceration of the 
arterial lesion and hemorrhage. The surface of the lesion 
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exposes its content to the arterial lumen leading to 
platelet aggregation and thrombus formation which become 
encrusted on the atherosclerotic plaque or atheroma 
(Robbins and Kumar 1987; King et al. 1983). 
In contrast to the fatty streak and the fibrous 
plaque, the media is very much involved in the necrotic 
process as its thickness is markedly reduced. The 
hypertrophy of the smooth muscle cells as they become 
engorged with lipid leads to the disruption of the 
composition of the media by decreasing the 
elastin/collagena ratio. The proliferation of these cells 
reduces the thickness of the media as smooth muscle cells 
migrate into the intima, while the remaining elastic fibers 
become diluted in collagen that has been oversynthesized by 
the surrounding myointimal cells(Woolf 1983). 
Moreover, the ulceration of the complicated plaque 
leads to further reduction of the diameter of the lumen of 
the artery. This condition may allow the blood from the 
arterial 1 umen to gain access into the atherosclerotic 
plaque precipitating the rupture of the atherosclerotic 
lesion (Woolf 1983). This partial reduction in the arterial 
lumen may not cause significant occlusion of big arteries 
like the abdominal artery and the aorta, but it can cause 
great damage to the media of the smaller coronary vessels 
which may lead to "atherosclerotic aneurysm" (Robbins and 
Kumar 1987). Complicated atherosclerotic 1 esions affect 
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blood flow by reducing the availability of blood to the 
heart. The development of ischemic heart disease (IHD}, due 
to decrease blood flow, may develop leading to recurrent 
episodes of angina pectoris {Soucek et al. 1984}. 
The lipid contained in the atheroma or complicated 
plaque exists in three chemical states, each with different 
densities. These are phospholipid, cholesterol ester, and 
free cholesterol. Small ( 1988) separated the 1 ipid 
contained in the complicated plaque using a sucrose medium. 
The uppermost layer consisted mainly of cholesterol ester 
lipid droplets. If one visualizes the point at which the 
cholesterol ester separates in the sucrose preparation in 
the context of the gruel or complicated plaque it follows 
that since these cholesterol droplets are less dense, they 
will be at the crest of the atherosclerotic plaque. 
However, the presence of cholesterol ester together with 
phospholipid indicates that as more cholesterol ester 
accumulates in the complicated plaque, the lipid droplets 
tend to penetrate deeper into the atherosclerotic lesion 
and hence unavailable to efflux into the arterial lumen. 
This intermediate phospholipid layer gives way to the next 
layer of lipid which is rich in cholesterol monohydrate 
crystals. These cholesterol crystals come from the 
cholesterol ester that has made its way through the 
plaque's crest and the phospholipid present in the 
atherosclerotic lesion. These cholesterol crystals tend to 
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be very stable, and their location furthest from the crest 
of the plaque prevents their efflux into the blood stream 
(Small 1988). However, these can be dissolved in 
cholesterol ester which, under specific experimental 
conditions (size of the crystals, temperature) serves as a 
solvent of cholesterol monohydrate crystals (North et al. 
1978). North, Katz and Small {1978) suggest that, even 
though cholesterol crystals seem to be inert, the 
dissolution of cholesterol monohydrate crystals into 
cholesterol ester oil is not a rate-limiting step in the 
reversal of an atherosclerotic plaque, but it is rather the 
transport of cholesterol ester out of the endothelium. If 
transport of dissolved cholesterol could be enhanced, 
cholesterol monohydrate crystals could be rapidly dissolved 
facilitating the reversal of atherosclerotic lesions 
(North, Katz and Small 1978). The transport of cholesterol 
out of the endothelium may well be augmented by the use of 
low cholesterol diets and/or hypo<?holesterolemic, agents 
which lower serum cholesterol. 
Due to the high stability of the cholesterol found in 
the complicated plaque or atheroma, Small and other 
researchers (Small et al. 1984; Katz et al. 1982) concluded 
that the turnover rate of cholesterol in the atheroma is 
very slow, when compared to the turnover rate of 
cholesterol in muscle, skin, and even in tendon. This is 
attributed to the fact that the atheroma has three phases 
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of cholesterol content and each lipid phase has different 
physicochemical characteristics. The turnover rate of 
cholesterol in the liquid phase (cholesterol ester 
droplets) is not as slow as the phospholipid and the 
crystalline phases where cholesterol appears to be almost 
inert for lipid mobilization (Small 1988). However, it does 
not mean that cholesterol cannot be mobilized, but rather 
that the actual mobilization of cholesterol from 
atherosclerotic lesions is a very slow process. 
The properties of these morphologically distinct 
stages of atherosclerotic development may give us clue to 
understand which treatments may be more useful for a 
successful approach to alter the atherogenic process. 
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Lipid and Cholesterol Metabolism 
Lipids are, by definition, chemical compounds that are 
water insoluble as a result of the nonpolar hydrocarbon 
regions that make a sizable proportion of their structure. 
The lipids are classified in three basic groups: the 
triglycerides, the phospholipids, and cholesterol. All 
three have biological importance in that they serve for 
different purposes in our body (Kirk 1980). 
The triglycerides are an important lipid source for 
the production and storage of energy in different metabolic 
processes. Phospholipids are the principal components of 
plasma membranes forming stable bilayers. Cholesterol plays 
an important role throughout the body as it regulates the 
fluidity of the plasma membrane and serves as the template 
for the biosynthesis of important molecules 1 ike 
steroids. 
Cholesterol is obtained from two main pathways, namely 
the exogenous pathway and the endogenous pathway. The 
exogenous pathway of cholesterol begins in the intestine 
where dietary fat is absorbed by the intestinal microvilli 
and incorporated into particles called chyl omicrons and 
then delivered to the liver and the adipose tissue. 
Cholesterol is readily absorbed in the intestine with the 
help of hepatic bile which is composed of cholesterol, bile 
salts, lecithin and other inorganic salts helping in the 
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emulsification process of fats (Ganong 1987). The 
chylomicron particle has specific apoproteins, apoprotein 
B-48 and apoprotein E, which are cleared by the liver 
through a receptor mediated endocytosis clearance pathway. 
The endocytosed cholesterol is esterified in the liver by 
the enzyme acyl cholesterol CoA: acyltransferase (ACAT) and 
is stored in the ester form until needed (Grundy 1986). The 
liver, in turn, delivers the necessary cholesterol, 
phospholipid and triglyceride in association with the 
lipoproteins to the rest of the body. 
An integral part of the metabolism of lipids is their 
transport in the blood. Lipids are insoluble in water. 
Although 91% of the plasma in which blood cells are 
suspended is water (Woolf 1983), the total 1 ipid 
concentration in our blood achieves levels of 300-750 
mq/dl! The dilemma is resolved by the fact that lipids are 
part of a complex with specific proteins at different 
concentration percentages. The proteins that are associated 
with 1 ipid are referred to as 1 ipoproteins. And these 
particles are part of the endogenous pathway of cholesterol 
metabolism. 
The different types of 1 ipoprotein containing 
particles, in addition to the chylomicrons, vary in their 
concentration of lipid and protein and therefore in 
densities. The three main lipoprotein classes are: 1) the 
.a-lipoproteins or low density lipoproteins (LDL); 2) the 
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pre-B lipoproteins or very low density lipoproteins (VLDL); 
and 3) o:-1 ipoprotein or high density 1 ipoprotein (HDL) 
(Kaplan et al. 1988). The protein constituent associated 
with the lipids are called apoproteins (Flier ed. 1985). 
The purpose of the apoproteins is mainly recognition by the 
different receptors and enzymes that will act on the 
lipoprotein for their metabolism. 
The very 1 ow density 1 ipoprotein is formed in the 
liver by a process very similar to that which takes place 
in the intestine for the synthesis of chylomicrons, 
including the utilization of apoprotein B as the major 
component of this lipoprotein. However, VLDL has a larger 
protein than the one used in chylomicrons, called 
apoprotein B-100. VLDL is transported to adipose tissue and 
other extrahepatic tissues. As it leaves the liver, VLDL 
also requires the addition of apoprotein C so that the 
particles are recognized as a substrate for the enzyme 
lipoprotein lipase. As the enzyme removes triglyceride from 
the VLDL core, the particle is reduced in size as i ~ 
increases in density. Once most of the triglyceride is 
metabolized by the action of lipoprotein lipase, apoprotein 
Cis lost from the molecule (Ganong 1987). 
However, VLDL has a role which transcends 
triglyceride 
precursor of 
triglyceride 
transporting 
low density 
concentration 
function, since VLDL is 
lipoprotein (LDL). As 
decreases further under 
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this 
the 
the 
the 
action of lipoprotein lipase, the final product results in 
the formation of LDL (Vander et al. 1985). The LDL particle 
serves as the major lipoprotein for the transport of 
cholesterol and cholesteryl esters (Rifkind and Levy 1977). 
In steroid biosynthesis, LDL provides the lipid necessary 
for the conversion of cholesterol into steroids. LDL is 
also the main lipoprotein for the transport of lipid back 
to the liver where it can be fused with more triglyceride 
to regenerate more VLDL particles or for the conversion of 
cholesterol into bile acids (Ganong 1987). 
The role of LDL in the regulation of cholesterol 
metabolism is due mainly to the presence of the low density 
lipoprotein receptor which recognizes the apoprotein B-100 
moiety on the LDL particle. However, the intermediate of 
VLDL, namely intermediate density lipoprotein (IDL), also 
bears apoprotein B-100 but more importantly apoprotein E, 
which has a higher affinity for the LDL receptor and 
consequently it is cleared from the circulation at a higher 
rate than LDL. Because the LDL particle only has apoprotein 
B-100 which has lower affinity for the LDL receptor than 
apoprotein E, the LDL particle has a longer half life (ti) 
than IDL particles and the LDL achieves higher cholesterol 
concentrations in plasma (Mahley and Innerarity 1983). 
Much of our understanding of the regulation of 
cholesterol metabolism has come from the studies of Michael 
s. Brown and Joseph L. Goldstein whose investigations using 
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cultured fibroblasts from both normal individuals and those 
suffering from familial hypercholesterolemia {type II 
hyperlipidemia) led to the discovery of the LDL receptor. 
When Brown and Goldstein began their work in 1972 in 
an attempt to understand the genetic disease known as 
fami 1 ial hypercholesterolemia, they found that the 
concentration of cholesterol in the blood of these patients 
was elevated many times above normal and heart attacks 
tended to occur early in life. They postulated that "this 
dominantly inherited disease results from a failure of the 
end product repression of cholesterol synthesis. The 
genetic disease of familial hypercholesterolemia was shown 
to be caused by inherited defects in the gene coding for 
the LDL receptor which disrupted the normal uptake of 
cholesterol and therefore control of cholesterol 
metabolism" (Brown & Goldstein 1986). The discovery of the 
LDL receptor earned Brown and Goldstein the Nobel Prize in 
Physiology and Medicine in December 9, 1985. 
In an article written in 1979 and published in Nature, 
Brown, Anderson and Goldstein first described their 
understanding about the process by which the LDL receptor 
recognized the LDL particle and induced receptor-mediated 
endocytosis. "The macromolecules that bind to speci fie 
cell-surface receptors are internalized via coated pits at 
a much greater rate than the rate at which substances 
dissolved in the extracellular space enter cells by fluid 
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phase endocytosis". Cholesterol uptake by cells proceeds by 
the former fashion. If this uptake is blocked, cholesterol 
accumulates in the blood and can contribute to the 
formation of atherosclerotic plaques in the blood vessel 
walls (Brown et al.l979, Alberts et al. 1983). 
The structure of the human LDL receptor is described 
by Brown and Goldstein as a large complex molecule made up 
of cysteine rich regions of about 292 amino acid residues 
that binds LDL (ligand binding domain); a region of about 
400 amino acid residues that is homologous to the precursor 
for epidermal growth factor; a 58 amino acid region that is 
rich in serine and threonine and is the site of 
glycosilation by C-linked sugars; a stretch of 22 
hydrophobic amino acid residues that spans the cell 
membrane; and a portion of 50 amino acid residues that 
projects into the cytoplasm (Ganong 1987). The LDL receptor 
is synthesized in the rough endoplasmic reticul urn as a 
precursor that contains high mannose N-linked carbohydrate 
chains and a core sugar (N-acetyl-galactosamine) of the c-
linked chains (Brown & Goldstein 1986). 
The genetic defects which cause familial 
hypercholesterolemia arise from mutation in LDL receptor 
biosynthesis. These mutations do happen at different points 
of the process, namely: 
a) the receptors are not synthesized; 
b) the receptors are slowly transported from the 
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rough endoplasmic reticulum to the Golgi 
apparatus; 
c) receptor may fail to bind LDL normally; 
or d) the receptor may fail to cluster in coated 
pits and endocytose the LDL particle (Brown & 
Goldstein 1986). 
One of the most important functions of the LDL 
receptor in living organisms was elucidated from the 
results of the studies performed on Watanabe Heritable-
Hyperlipidemic (WHHL) rabbits. These rabbits had a mutation 
in which the LDL receptors, although synthesized, were 
slowly transported from the rough endoplasmic reticulum to 
the Golgi apparatus where the receptor protein gets 
glycosilated. When the genetic defect was present in the 
homozygous form, the LDL cholesterol levels were extremely 
high and the rabbits developed atherosclerosis very 
rapidly. Normally, when there is accumulation of free 
cholesterol in the cell the activities of two microsomal 
enzymes are altered: 1) 3-hydroxy-3-methylglutaryl Coenzyme 
A {HMG-CoA) reductase which is the rate-limiting step in de 
novo synthesis of cholesterol is suppressed; and 2) acyl 
cholesterol CoA: acetyltransferase (ACAT) which esterifies 
free cholesterol is activated. Accumulated cholesterol also 
causes the feedback inhibition of LDL receptor synthesis. 
In the Watanabe rabbits it was found that the low metabolic 
degradation of LDL particles and the overproduction of LDL 
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were associated with the absence of a mechanism to increase 
the biosynthesis of LDL receptor, thereby increasing the 
cholesterol concentration in the blood (Watanabe 1980). Now 
it is understood that the absence of the LDL receptor is 
considered, at least in part, responsible for 
hypercholesterolemia and the precipitation of the 
atherosclerotic process. 
Experimental data have indicated that modifications on 
the lipid constituents of the LDL particle may exert its 
atherogenic properties by routes other than the interaction 
between LDL and its specific receptors. Several reports 
have actually demonstrated that LDL induces cytotoxicity, 
injury, or inhibition of proliferation of cultured 
endothelial cells. Such toxicity needs the presence of 
modified LDL which probably occurs as a result of LDL 
lipoprotein oxidation (Malmendier et al. 1987}. 
Therefore, if the LDL receptor mediates the removal of 
the LDL from plasma, the maneuvers that increase LDL 
receptor activity or number will affect the rate at which 
the LDL particles are metabolized. Pharmacological 
treatments have been developed which lower plasma LDL and 
cholesterol concentrations. These therapeutic regimes shall 
be discussed in detail in the section about 
hypocholesterolemic agents. 
While high levels of LDL particles are associated with 
a high risk for atherosclerotic development, another 
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lipoprotein of the endogenous pathway of cholesterol 
metabolism, high density lipoprotein (HDL), has been 
suggested to have an opposite effect in reducing total 
plasma cholesterol levels (Miller and Miller 1975; Erickson 
and Carlson 1973). That is, HDL is believed to function in 
reverse transport or eff 1 ux of cholesterol out of the 
arterial wall (Boucek et al. 1984). The hypothesis that HDL 
may play a role in reverse cholesterol transport was first 
proposed by Glomset (1968). Later, Carew et al. (1976), in 
studying the role of HDL in cellular cholesterol efflux, 
demonstrated that HDL had the same capability to bind to 
endothelial cells in pigs as LDL. But HDL internalized 
cholesterol whereas LDL deposited cholesterol in the 
arterial wall (Carew et al. 1976). 
HDL, like LDL, is also synthesized in the liver and 
contains several different apoproteins including apoprotein 
A, apoprotein C, and apoprotein E. The latter two 
apoproteins are released by HDL into the circulation and 
taken up by both chylomicrons and VLDL (Stryer 1981). The 
HDL particle contains 50\ protein, 25\ phospholipid, 15\ 
cholesterol ester, 5\ free cholesterol and 5\ triglyceride. 
HDL has two types of apoprotein A, apoprotein AI and 
apoprotein AI I in a 4:1 ratio. Whi 1 e apoprotein AI is 
important for the activation of LCAT, apoprotein AI I is 
responsible for the proper activation of the enzyme 
lipoprotein lipase (Woolf 1982). 
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"Free cholesterol from extrahepatic tissues is 
transferred to HDL. It is esterified by LCAT, enablinq HDL 
to take up more free cholesterol. Esterified cholesterol 
formed in HDL is then incorporated into the LDL lipid core 
. The LDL, carryinq a load of cholesteryl ester, reaches 
the liver where these cholesteryl esters are hydrolyzed. 
Free cholesterol so formed enters the pool of free 
cholesterol in the liver that is available for removal by 
the bile, conversion into bile acids or reincorporation 
into plasma lipoproteins" (Woolf 1982). 
HDL is also involved in the removal of cholesterol 
from various orqans and tissues, and indirectly 
transportinq cholesterol ester to the 1 i ver for further 
metabolism (Ganonq 1987). If the effectiveness of this 
reverse cholesterol transport system is directly 
proportional to the concentration of HDL in the plasma, the 
neqati ve correlation between HDL 1 evel s and the risk of 
development of atherosclerosis may indicate that reverse 
cholesterol transport is important in removinq cholesterol 
out of the endothelium (Steinberq 1987). However, there are 
sti 11 no totally conclusive demonstrations in vivo of 
reverse cholesterol transport (Steinberq 1987). Since 1973 
there has been data to indicate that the concentration of 
HDL is neqatively correlated (Miller 1980) with the 
incidence of coronary heart disease (CHD), and that is why 
it has been commonly referred to as "qood cholesterol". In 
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experiments performed by Miller and Miller (1975) it was 
shown that the body cholesterol pools increase with 
decreasingHDL concentration. And when coronary angiography 
was performed in 104 men between the ages 35 and 65 years, 
it was discovered that the men with high coronary scores 
(i.e., more atherosclerotic lesions) tended to have lower 
plasma HDL concentrations than those of similar age with 
low coronary scores (Miller et al. 1981). Some 
investigators suggest that a low concentration of HDL may 
increase the susceptibility to atherosclerosis but not that 
low concentrations of HDL accelerate the rate of the 
atherogenic process (Tan et al. 1980; Miller et al. 1981). 
Thus, whether a high HDL level protects against coronary 
heart disease or whether low levels of HDL may predispose 
an individual to coronary heart disease is still uncertain 
(Woolf 1982). 
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Foam Cells and Cholesterol 
The mechanisms by which lipid accumulates in the 
arterial intima as a result of endothelial injury are very 
complex. The biochemical steps of atherogenesis have not 
yet been completely elucidated.There are several theories 
about the mechanisms by which the body is able to cope with 
the problem of intimal lipid accumulation and the ways the 
vascular system resolves such lesions. 
The "response to injury" hypothesis of atherosclerosis 
is now widely held as most consonant with the large body of 
accumulated data. This theory, as presented by Robbins and 
Kumar (1987), states that; "(1) atherosclerosis is 
initiated as a response to various forms of injury to the 
arterial endothelium; and (2) endothelial injury leads to: 
(a) attachment of monocytes and platelets to the intimal 
surface; (b) proliferation of smooth muscle cells in the 
arterial intima; (c) synthesis by these cells of large 
amounts of connective tissue matrix, including collagen, 
elastic fibers, glycosaminoglycans (GAGS), and 
proteoglycans; and (d) depositions of intracellular and 
extracellular lipid that eventually results in the 
formation of a pool of lipid and cell debris in the core of 
advanced lesions" (Robbins and Kumar 1987). 
According to this hypothesis, two main cell types 
contribute to the "response to injury" on the arterial 
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wall, namely the monocytes and smooth muscle cells. Both 
give rise to a single and histopathological form known as 
the foam cell: a characteristic subendothelial accumulation 
of lipid that conglomerate within cells as droplets giving 
these a foamy appearance (Robbins and Kumar 1987). 
Furthermore, abundant epidemiological, experimental and 
clinical data adjudge a primary atherogenic role of lipid 
accumulation and foam cell formation to LDL-cholesterol, 
the major component of the lipid content in plaques (Smith 
1974; Smith and Slater 1972; Steinberg 1987). LDL and 
certain plasma proteins accumulate in the internal layers 
of the atherogenic wall. And it has been demonstrated that 
the amount of detectable LDL in the intima-media of human 
arteries correlates very well with the circulating levels 
of plasma LDL (Bourne 1985). Foam cells arise as a result 
of such lipid accumulation in the internal layers of the 
arterial wall. 
Foam cells are derived from two cellular sources: the 
arterial smooth muscle cells and the monocyte derived 
macrophages (Malmendier et al. 1987). First, macrophages in 
the atherosclerotic lesion are thought to be derived from 
monocytes. "The factors responsible for the attraction of 
monocytes to the arterial wall are poorly understood. 
Chemotactic factors have been described as well as changes 
in the endothelial cells themselves induced by agents such 
as viruses, that enhance monocyte sticking. Monocytes are 
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observed adhered to the endothelium over an atherosclerotic 
plaque" (Bates & Gangloff 1987). Woolf (1882) reports that 
Adams and colleagues have shown that macrophages are 
"indeed present in the 1 esions of both human and rabbit 
atherosclerosis, since these cells can be identified 
histochemically by the use of either catalase or 
cytochrome-oxidase techniques". 
A general consensus that some foam cells are derived 
from mononuclear phagocytes was reached in the years 1960-
1962 on the basis of electron microscopic examination of 
experimental and human atherosclerotic lesions (Woolf 
1982). "These mononuclear phagocytes may originate either 
from the circulating blood or wandering tissue histiocytes, 
but they phagocytize fat in situ, i.e., in the intima. 
However, this is not the initial step in the evolution of 
the lesion as it represents a sequence to an earlier change 
involving the native cells (endothelial cells)" (Geer & 
Haust 1972). It is at the fatty streak stage that the 
rnacrophages appear to be the predominant element in the 
foam cell population. These macrophages are not only the 
most common source of foam cells, but also they can easily 
ingest extracellular cholesterol from the arterial wall and 
metabolize it providing the means for excess cholesterol 
removal (Brown, Ho and Goldstein 1980). It is still not 
clear how macrophages can internalize the cholesterol in 
the intima and how these cells are recycled so that new 
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macrophages can arrive at the site of excess cholesterol 
accumulation and remove it effectively. But data from 
observations using scanning and transmission electron 
microscopy suggests that macrophages can actually penetrate 
the arterial wall through the tight junctions of the 
endothelium enabling these to removed the lipid trapped 
within the arterial wall. And, as suggested before, some 
investigators believe that atherosclerotic lesions generate 
chemoattractants that recruit circulating monocytes to the 
intima by monocytes (Stary 1987). 
Macrophages are not the only type of lipid-laden cell 
in the atherosclerotic plaque. Smooth muscle cell-derived 
foam cells have also been described (Gown 1986). The first 
reports of lipid phagocytic activity by smooth muscle cells 
was made by Jeres in 1903 when he noticed a "mixed type of 
hyperplasia of the musculo-elastic layer with fatty 
degeneration and superimposed proliferation of connective 
tissue" (Woolf 1982). But it was not until 1960 that fat-
containing smooth muscle cells were unequivocally 
identified in the fatty streaks of experimental and human 
atherosclerosis with the help of the electron microscope. 
In the early atherosclerotic lesions (fatty streaks) 
lipid accumulates inmacrophages and later in smooth muscle 
cells. Hence, foam cells result from the accumulation of 
large amounts of fat in both types of cells (Geer & Haust 
1972). Through histological analysis, fat accumulation in 
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smooth muscle cells 
inclusion containing 
1982). 
appears 
strands 
as reticulated cytoplasmic 
of dense material (Woolf 
Unlike macrophages which can be made to accumulate large 
amounts of cholesteryl ester in vitro as demonstrated by 
the detection of lipoprotein-antibody complexes, smooth 
muscle cells do not have receptors for modified 
1 ipoproteins and the synthesis of LDL receptors of the 
latter are efficiently down regulated with small increases 
in cellular cholesterol. Smooth muscle cells internalize 
the lipid by mechanisms that are still not known (Klimov 
1988) . 
Even though extensive experimentation has not been 
performed to outline the actual mechanisms of foam cell 
formation, very recent studies are bringing new evidence 
which may in part clear some uncertainties about foam cell 
cytogenesis. It was observed by Brown and Goldstein (1983) 
that cultured macrophages, in the presence of native LDL, 
were unable to convert into foam cells despite the high LDL 
concentration in the culture plates. This phenomenon gave 
rise to the postulation that "the circulating LDL particles 
must first undergo some kind of post secretory modification 
which then enables the macrophages to develop rapidly into 
a foam cell". They found that chemical acetylation 
converted LDL to a form which macrophages could endocytose 
more rapidly than native LDL particles. Moreover, it was 
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also found that smooth muscle cells in culture were also 
able to implement a similar modification of LDL particles 
into an oxidized or acetylated form (Hendriksen 1983). 
LDL particles in a medium with cells found in arterial 
wall underwent peroxidation of polyunsaturated fatty acids 
in the LDL lipid. The reaction for LDL modification takes 
place in the presence of a transition metal ion like copper 
or iron at low concentrations. The reaction is inhibited by 
the addition of a metal chelator like ethylenediamine 
tetraacetic acid (EDTA). The free fatty acid lecithin, 
present in LDL, is converted to LDL lysolecithin by the 
action of oxidative lipid modification. The enzymatic 
reaction for the conversion of LDL lecithin into LDL 
lysolecithin is carried out by the enzyme phospholipase A2. 
Although the precise mechanisms are not known, once some of 
the free fatty acid lecithin gets converted to 
lysolecithin, the reaction proceeds at a much faster rate, 
especially in the presence of low concentrations of metal 
ions (Steinberg et al. 1989). 
The cytotoxicity of oxidized LDL could conceivably, as 
once suggested by Malmendier et al. (1987), induce 
functional changes in the subendothelial space and thus 
accelerate the formation of the fatty steak and the 
subsequent accumulation of LDL cholesterol in the arterial 
intima (Steinberg et al. 1989). Furthermore, oxidized LDL 
is also a potent chemoattractant for circulating human 
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monocytes, an effect elicited by the lysolecithin generated 
during the conversion of LDL to its oxidized form {Quinn et 
al. 1987). 
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Atherosclerotic Regression and Diet 
Throug-hout this paper it has been suqqested that a 
hiqh cholesterol level promotes atherosclerosis. The 
question we must now address is what are the effects of 
lowering- the plasma cholesterol levels on coronary heart 
disease. In a consensus conference held in December 1984 by 
the National Institute of Health authorities on cholesterol 
and its relationship with cardiovascular disease arrived at 
the conclusion that reduction of blood cholesterol reduces 
the rate of coronary heart disease (Consensus Conference 
1985). Clinical trials and studies have provided evidence 
that the incidence of coronary heart disease can be 
ameliorated by reducing- chol estero! intake and 
supplementing- the diet with fiber and the administration of 
certain cholesterol lowering- druqs or hypolipidemic aqents 
(Consensus Conference 1985). Some of these diets and druqs 
that bel p reduce cholesterol 1 evel s is supported by a 
qrowinq body of evidence which indicates that the process 
of atherosclerosis is almost completely preventable and 
that it is substantially reversible (Wissler and 
Vesselinovitch 1977), both in primates and humans (Malinow 
1981). 
Atherosclerotic reg-ression, as defined by Malinow 
(1980), indicates anatomical changes observed after a 
drastic reduction in marked hypercholesterolemia induced by 
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diet. "At the microscopic level, regression includes: 
(1) restored integrity of the endothelium lining 
the plaques; 
(2) arrest of intimal cell proliferation; 
and (3) a decrease in the number of cells, in the 
amount of intracellular and interstitial 
lipid, and in the extent of necrotic and 
calcified foci in the plaques". 
Atherosclerotic ~egression occurs in a stepwise 
fashion. First, capillary sprouts derived from endothelial 
cells penetrate the atherosclerotic plaque clearing debris 
from the lesion and oxygenating the area to be repaired 
(Adams 1984). Second, blood-borne monocyte/macrophages 
transmigrate into the arterial wall and phagocytize the 
debris (Gaton & Wolman 1984). Finally, the structure of the 
arterial endothelium is repaired by the action of 
fibroblasts which synthesize collagen restoring the 
arterial wall to normal thickness resul tin9 in a , fibrous 
scar on the vessel wall which has a low content in ground 
substance and cells (Linder et. al 1984). 
In order to achieve atherosclerotic regression, 
accumulated cholesterol must be removed or at least lowered 
in concentration in the lesion as well as in blood. Thus 
the aim of inducing re9ression by initiating a diet or 
other lipid lowering regimens, is to decrease the size of 
the atherosclerotic plaque which may be occluding blood 
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flow (Wissler and Vesselinovitch 1977). 
cholesterol is lowered to 150mg/dl, lipids 
"When plasma 
are mobi 1 i zed 
from the lesions and regression gradually occurs. This loss 
of 1 ipid reduces the vel ume of the 1 esion appreciably, 
which should increase luminal area an blood flow and 
ameliorate the clinical effects of the disease. After 
prolonged periods of low plasma cholesterol, cholesterol 
esters and foam cells disappear and [cholesterol 
monohydrate crystals] gradually dissolve, leading to true 
regression" (Small 1988). 
In a human prospective study performed by Dr. 
Buschwald from the University of Minnesota School of 
Medicine, regression of coronary 1 esions based on 
sequential arteriograms occurred after a partial ileal 
bypass (i.e., removal of a section of the ileum (Wissler 
and Vesselinovitch 1977). This surgical procedure appears 
to elicit regression by reducing the intestinal surface 
available for absorption of bile acids which diminiihes the 
absorption of cholesterol and increases hepatic expression 
of LDL receptors (Barndt et al. 1977). A year later, 
Blankenhorn presented a summary of human angiographic 
studies in which a considerable number of study groups 
reported cases of atherosclerotic regression. It was 
Blankenhorn's impression that most of these studies were 
performed on the femoral artery because it offered the 
advantage of being more accessible for observation than 
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coronary arteries. 
Blankenhorn (1977) 
Some of 
have 
the studies 
indicated 3 
provided 
cases 
by 
of 
atherosclerotic regression out of 31 patients and in others 
9 cases of atherosclerotic regression out of 25 patients. 
The fact that these observations were assessed by only two 
serial femoral angiographies in each case, the short length 
of these studies and the variable severity of 
atherosclerotic lesions may have posed some limitations to 
the interpretation and results of these studies. A case 
report of a 46 year old white male who suffered from 
exertional angina and mild hyperlipidemia showed a 
spontaneous regression based on a series of arteriograms of 
the left anterior coronary artery upon modification of his 
diet to a low cholesterol intake which reduced his blood 
cholesterol level (Roth and Kostuk 1980). Although it is 
just a single case atherosclerotic regression, this is a 
representation of the possibility of atherosclerotic 
regression in humans. 
Atherosclerosis is due mainly to an eleva ted 
concentration of cholesterol. Much of this cholesterol 
arises as a result of a diet high in saturated fat. The 
first step in treating high levels of cholesterol is by 
modifying the diet. Phillipson and colleagues (1985) they 
discovered that dietary fish oil, which is rich in 
polyunsaturated fatty acids, had profound hypolipidemic 
effects on each of the 20 patients diagnosed with 
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hypertriglyceridemia. The total plasma cholesterol and 
triglyceride fell in every patient without exception. 
Polyunsaturated fatty acids like linoleic acid (C 18:21 w-
6) and oleic acid (C 18:1 w-9) have hypocholesterolemic 
properties. When compared' with saturated fatty acids, both 
types of unsaturated fatty acids caused similar reduction 
in the LDL cholesterol level. In contrast, linoleic acid 
lowered the HDL cholesterol while oleic acid did not. This 
perhaps could account for the apparent extra 
hypocholesterolemic effect of linoleic acid over oleic 
acid. The capability of polyunsaturated fatty acids to 
lower serum cholesterol appears to have a beneficial effect 
in the incidence of coronary heart disease. Diets high in 
polyunsaturated fat seem to influence the composition of 
arterial tissues and atheromas by reducing the availability 
of cholesterol (Dayton et al. 1965) However there was no 
concrete evidence in this study on whether or not 
polyunsaturated had the capability of pr'omoting 
atherosclerotic regression. Both fatty acids act in the 
liver replacing- the saturated fat pool for lipoprotein 
metabolism, although they have no known effect on the LDL 
receptor (Grundy 1986). 
The most convincing evidence of regression of advanced 
atherosclerosis in non-human primates was performed by 
Armstrong and Megan (1972). They reported that prominent 
atheromatous lesions in the coronary arteries decreased in 
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their cholesterol content when monkeys were fed a high fat 
diet and then placed in a diet high in polyunsaturated fat 
for 40 months. Also there was a significant decrease in 
collagen and elastin content in the atherosclerotic 
arteries (Armstrong and Megan 1972). Atherosclerotic 
regression in these monkeys was suggested by the fact that 
the lumen of the coronary arteries increased in size and 
because the reduction in the thickness of the intima was 
accompanied by a decrease in the lipid content of the 
arterial wall. These studies have also been repeated and 
supported by other investigators (Malinow 1980; Clarkson at 
al. 1979; Wagner, St. Clair and Clarkson 1980). 
Dietary fiber has also important hypocholesterolemic 
effects and may reduce risk for coronary heart disease 
(Anderson 1987; Anderson & Tietyen-Clark 1986). These 
endogenous components of plant materials in the diet that 
are resistant to digestion by enzymes produced by man can 
be classified into water-insoluble fiber (e.g. wheat bran 
and alfalfa) which decrease transit time and fecal weight; 
and water-soluble fiber (e.g. oat bran) which have shown to 
decrease the glycemic response of foods and lower 
cholesterol concentration (Anderson 1987). A diet low in 
cholesterol and high in dietary fiber may achieve serum 
cholesterol reductions exceeding 20\ by the implementation 
of a diet high in fiber which may lower the risk for 
coronary heart disease and may even reverse the 
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atherosclerotic process (Anderson & Tietyen-Cl ark 1986). 
Barndt et al. (1985) demonstrated that after 25 patients 
were treated with a combination of a high fiber diet (which 
resulted in weight 1 oss) and hypochol esterol ernie drugs, 
femoral angiography revealed regression-of atherosclerotic 
lesion. The regression of the atherosclerotic lesion in the 
femoral artery was accompanied by a significant reduction 
in plasma cholesterol levels. However, the regression 
observed in this study was only observed on atherosclerotic 
plaques that were small and not very much developed. 
Lesions that have not developed into complicated plaques 
regress more rapidly because their cholesterol turnover is 
faster. Studies performed by Katz et al. (1982) on 
cholesterol turnover suggest that cholesterol ester 
droplets located proximal to the arterial lumen can leave 
the arterial wall more rapidly if the atherosclerotic 
lesions have not developed into extremely necrotic lesions. 
Thus, if cholesterol levels are lowered and in turn the 
rate of cholesterol efflux is enhanced, then small 
atherosclerotic lesions (fatty streaks and intermediate 
plaques) can regress rapidly, and complicated lesions may 
also regress but at a much slower rate. 
When water-soluble fibers from oat bran and bean 
products were incorporated into a diet low in fat and 
cholesterol for hypercholesterolemic men, serum cholesterol 
concentrations decreased 26\ bel ow initial values at 24 
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weeks and decreased 23\ below initial values at 99 weeks 
(the 1 atter 3\ increase resulted from an increased HDL 
concentration). Previous studies in humans and rats have 
shown that oat bran intake lowers serum LDL cholesterol 
concentrations and raises the HDL concentrations (Kirby et 
al. 1981). Other human and animal studies suggest that 
these hypocholesterolemic effects of oat bran are related 
to the water soluble gum, B glucan (Anderson et al. 1984). 
The mechanisms responsible for the hypocholesterolemic 
effects of oat bran and other water-soluble fibers are 
still under intensive investigation. However it is thought 
that oat bran may act as a bile-acid binding agent which 
accelerates the removal of LDL cholesterol from the 
peripheral circulation (Anderson 1987). Although there is 
no evid~nce that oat bran actually induces atherosclerotic 
regression, its mechanism of action is suggested to be 
similar to that of the synthetic bile acid binding resins 
and therefore may prove useful in the future in the 
treatment of atherosclerosis. 
In studies performed by Malinow and colleagues (1978), 
a decrease in serum cholesterol levels, normalization in 
the distribution of plasma lipoproteins, and reduction in 
the extent of aortic and coronary atherosclerosis was found 
when monkeys (macaca fascicularis) were fed a semipurified 
diet containing alfalfa. Even though these were fed a usual 
American diet, that study suggests that alfalfa counteracts 
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the atherogenic effect of dietary chol estero I. A diet 
consisting of 50\ monkey chow and 50\ alfalfa reduced 
plasma cholesterol from 287 ± 23mg/dl to 200mg/dl. In the 
group of monkeys receiving alfalfa there was evidence of 
"healing" from aortic and coronary atherosclerotic lesions 
caused by an atherogenic diet. The foam cells population 
was either very low or completely absent in the coronary 
arteries. The intimal lumen widened although the intima was 
thicker than normal. And the accumulation of fat-laden 
cells in the adventitia had largely disappeared. Malinow 
(1980) suggests that "the mechanism by which alfalfa may 
counteract atherogenicity of dietary cholesterol might be 
due to the insoluble complexes formed by alfalfa saponins 
with cholesterol which tend to precipitate micellar 
cholesterol suspension restricting their diffusion and 
impairing their absorption" (Malinow et al. 1978; Malinow 
1980). A simi 1 ar study performed by Srinivasan et al . 
(1980) in monkeys (macaca fascicuiaris) also showed that 
alfalfa produced a decrease in aortic tissue lipids. 
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Atherosclerotic Regression and Druq Treatment 
Decisions to use drug therapy for hyperlipidemia must 
be based on the specific physiologic defect and its 
potential for causing atherosclerosis. Dietary measures, 
like the ones described in the previous section, are always 
initiated first and may obviate the need for drugs (Katzung 
1987}. The use of these drugs in the treatment of 
atherosclerosis is based on the effect that these exert on 
plasma lipoproteins. Some hypolipidemic drugs could act as 
agents of regression by either lowering the availability of 
exogenous cholesterol, decreasing the synthesis of 
endogenous cholesterol, or by altering lipid catabolism and 
hence the total lipid profile (Yong and Koda-Kimble ed. 
1988) . 
One of these hypocholesterolemic agents, 
cholestyramine, was originally used to control pruritus in 
patients with elevated concentrations of bile acid'due to 
cholestasis (Goodman and Gilman 1985). The bile acid 
binding resins are one of the drugs of used for the 
treatment of patients with primary hypercholesterolemia, 
particularly those with heterozygous familial 
hypercholesterolemia (Illingworth 1987}. Colestipol 
(Colestid) and cholestyramine (Questran) are useful only in 
hyperl ipoproteinemias involving LDL elevations. Tennent 
(1959) reported that a significant reduction in plasma 
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cholesterol occurred in dogs fed cholestyramine and 
subsequent studies have demonstrated that cholestyramine is 
a very effective drug for reducing plasma cholesterol and 
LDL in man (Rifkind and Kevy 1977). 
Cholestyramine and colestipol are basic anion exchange 
resins, quaternary anunonium chlorides able to exchange 
chloride for the chelate ion of the bile acid (Meyers et 
al. 1980), hence often referred to as ion-exchange resins. 
They bind bile acids in the intestinal lumen and prevent 
their absorption (Katzung 1987). Once the chloride ion is 
exchanged for the bile acid, the complex so formed is 
unabsorbed as it is eliminated in the feces (Goodman and 
Gilman 1985). Colestipol hydrochloride is a tetraethylene-
pentamine and epichlorhydrin copolymer(Kuo et al. 1979). If 
the bile acids are bound by a resin like cholestyramine or 
colestipol, their daily excretion is greatly increased 
(Meyers et al. 1980; Illingworth 1987). Studies in normal 
and hypercholesterolemic subjects 4emonstrated that bile 
acid binding resins markedly increase the fecal excretion 
of bile acids {Rifkind and Levy 1977).The hydroxylase 
enzyme that is responsible for the synthesis of bile acid 
from cholesterol is normally inhibited as bile acid feeds 
back in its synthetic pathway. However, if there is little 
or no bile acid returning through the enterohepatic 
circulation, then the inhibition of the hydroxylase enzyme 
is removed and it increases the synthesis of more bi 1 e 
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acids from cholesterol (Goodman and Gilman 1985). In 
response, the 1 i ver increases the biosynthesis of LDL 
receptors which consequently leads to even further decrease 
in the concentration of LDL cholesterol (Goodman and Gilman 
1985) . 
The bile acid binding resins have no beneficial effect 
on patients who suffer from the homozygous form of familial 
hypercholesterolemia because the genes that code for the 
LDL receptor are not functional in these individuals. 
However, heterozygous have a partial mutation in the genes 
that code for the LDL receptor so that treatment with 
resins may prove useful (Katzung 1987). 
The National Heart, Lung and Blood Institute {NHLBI) 
Type II Coronary Intervention Study with 
hyperlipoproteinemic subjects showed that the group that 
was treated with cholestyramine achieved a 26\ reduction in 
the LDL-cholesterol while the group that was placed in a 
placebo achieved only a 5\ reduction (both averaged over 
the 5 year period of the follow-up), indicating a 
statistically significant (p< 0.001) effect of drug 
treatment on LDL cholesterol (Brensike et al. 1984). 
Reports of an increase in HDL concentration have also been 
described in which an increase in 16 to 21\ in HDL 
cholesterol levels with cholestyramine resulted in a 
1 owe ring of the total /HDL cholesterol ratio from 8. 0 at 
baseline to less than 4.7 (Hoeg et al. 1987). Studies with 
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Watanabe rabbits have shown that cholestyramine treatment 
early in life increases resistance to dietary cholesterol-
induced hypercholesterolemia and atherogenesis in adult 
life (Subbiah et al. 1987). 
Although the NHLBI Type I I Intervention study was 
unable to provide conclusive evidence of regression of 
atherosclerotic lesions, it suggests that the lowering of 
cholesterol elicited by the implementation of 
cholestyramine plus diet lowers the rate of progression of 
observed coronary atherosclerotic lesions assessed by 
arteril angiography (Brensike et al. 1984). The study could 
have been limited by the small sample of patients, and the 
lack of consistently strong, statistically significant 
angiographic observations which may have given a wrong 
indication about the beneficial effects from the use of 
cholestyramine. 
Studies in rhesus monkeys conducted by DePalma et 
al.(l979) revealed that regressive changes in the ~ortic, 
carotid and femoral arteries were produced when 
cholestyramine was added to an atherogenic diet. Regression 
of 1 esions was associated with 1 owe ring of serum 
cholesterol levels. Surgical and angiographic examinations 
were used in order to evaluate regression of experimental 
atherosclerosis (DePalma et al. 1979). When the treated 
animals had cholesterol levels lower than 250mg/dl for a 
period of 11 months, biopsy and angiographic evaluation 
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revealed evidence of plaque regression. At serum 
cholesterol levels above 300mg/dl, treated animals showed 
evidence of plaque regression at one site and progression 
at other sites. DePalma (1979) suggests that cholesterol 
1 evels above 300mg/dl may be a threshold above which 
regression can no longer be achieved. Other investigators 
have similar results with cholestyramine as an effective 
drug to lower cholesterol levels and to exert a regressive 
effect on the arterial wall of nonhuman primates (Wissler 
and Vesselinovitch 1977). 
Srinivasan and colleagues (1980) in experiments with 
macaca fascicularis showed that cholestyramine treatment 
produced a remarkable depletion of both free and esterified 
LDL cholesterol from aortic tissue and regression of 
atherosclerotic plaques after 18 months of treatment. 
Furthermore, Malinow (1980) reported that a group of rhesus 
macaques receiving cholestyramine had shown regression even 
with cholesterolemia around 300mg/dl. Scanning electron 
micrograph of the aortas of these monkeys showed that, in 
contrast to the intimal surfaces of the aortic plaques at 
the end of the induction period, the intimal surfaces of 
the aortic plaques at the end of the study were covered by 
a continuous endothelium. "Transmission electron microscopy 
showed tight junctions and basement membrane reduplication, 
probably signs of repair" (Mal in ow 1980; Weber et al. 
1977). 
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The resins are also used in combination with other 
drugs to achieve further hypocholesterolemic effect. One of 
these drugs is nicotinic acid, more commonly known as 
niacin. Nicotinic acid has been known for considerable time 
to reduce plasma cholesterol concentrations (Altschul et 
al. 1955; Carlson 1977). Nicotinic acid is a drug used for 
the treatment of patients with primary hypercholesterolemia 
(Illingworth 1987). The hypolipidemiclipid properties of 
nicotinic acid is separate from its role as a vitamin or 
coenzyme (Goodman and Gilman 1985). 
Nicotinic acid is a water-soluble vitamin. Nicotinic 
acid is incorporated into the body and through a series of 
amide additions and nucleotide synthesis reactions is 
incorporated into nicotinamide adenine dinucleotide {NAD). 
"It is excreted unmodified in the urine and as 
nicotinamide,N-methyl-2-pyridone-3-carboxyamide,N-methyl-
2-pyridone-5-carboxyamide, and other less abundant 
metabolites" {Katzung 1987). The normal human nutritional 
requirements for nicotinic acid is less that 30mg, while 
the doses required to lower serum cholesterol are often 100 
times as much {about 3000mg/day) {Dukes ed. 1988). 
Nicotinic acid has been demonstrated to be effective 
in 1 owering plasma cholesterol, LDL, trigl ycerides, and 
VLDL in various types of hyperlipoproteinemias. Nicotinic 
acid is readily absorbed from the gastrointestinal tract. 
However, the effect of nicotinic acid on VLDL and 
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triglyceride levels is more noticeable than the reduction 
of the cholesterol levels (Goodman and Gilman 1985). 
The primary mechanism of action of nicotinic acid 
involves the inhibition of VLDL secretion which in turn 
decreases the production of LDL and IDL. The precise 
mechanism by which nicotinic acid reduces plasma 
concentrations of VLDL and LDL is unknown (Katzung 1987). 
But it is likely related to several of the drug's diverse 
actions. Fat is stored in adipose tissue as triglycerides 
but is released from fat cells for transport as free fatty 
acids (Meyers et al. 1980). The basic mechanism of action 
of nicotinic acid probably lies in its ability to block 
lipolysis by inhibiting the intracellular lipase system of 
adipose tissue (Woolf 1982); which in turn reduces the 
levels of free fatty acids in plasma. Nicotinic acid may 
also decrease the hepatic esterification of triglycerides 
and decrease the activity of 1 ipoprotein 1 ipase as a 
possible direct effect on hepatic production of apoprotein 
B-100 (Illingworth 1987; Goodman and Gilman 1985). Due to 
the ability of nicotinic acid to effectively reduce VLDL 
levels, the combined therapy of bile acid sequestrants with 
nicotinic acid has been demonstrated to have a synergistic 
effect. 
Nicotinic acid did not appear to have any effect on 
mortality from coronary heart disease in rabbits 
(Parwaresch et al. 1978). Its effects on cholesterol levels 
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and the arterial intima have been reported in experimental 
studies (Woolf 1982). Parwaresch et al. (1978) showed that 
in rabbits after a period of atherogenic induction, 
nicotinic acid had a clear hypocholesterolemic and anti-
atherogenic effect as measured by plasma cholesterol 
concentrations and planimetric evaluation of the 
atherosclerotic lesions in the aorta. Nicotinic acid was 
able to increase HDL:LDL ratio (Parwaresch et al.1978). 
In 1981, I 11 ingworth et al. reported in The Lancet 
about the treatment of familial hypercholesterolemia (FH) 
with the use of nicotinic acid in conjunction with one of 
the bile acid binding resins, colestipol. Sequential 
treatment of thirteen patients with fat restricted diet, 
diet plus colestipol, and diet and colestipol and nicotinic 
acid revealed cholesterol levels of 415 ± 69 mg/dl, 327 ± 
54 mg/dl, and 246 ± 49 mg/dl, respectively. These results 
indicate the usefulness of combined drug therapy with a 
bile acid sequestrant and nicotinic acid to reduc~ plasma 
cholesterol levels in patient with heterozygous FH. 
Although the long term use of nicotinic decreased the 
progression of atherosclerotic lesions, this study in 
particular did not include any concrete evidence of 
atherosclerotic regression in FH patients (Illingworth et 
al. 1981). 
The Cholesterol-Lowering Atherosclerotic Study (CLAS) 
(Blakenhorn et al. 1987) which included study of nicotinic 
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acid suggested that blood cholesterol lowering has directly 
beneficial effects in human atherosclerotic lesions after 
venous bypass graft surgery. In this double blind study 
coronary angiography was performed by percutaneous femoral 
technique before the randomization of patients into a 
placebo and a nicotinic acid-colestipol group. Treatment 
produced significant reduction in progression (but not 
regression) of atherosclerosis in native coronary arteries 
and venous grafts. The CLAS is the first angiographic study 
providing clear evidence of a treatment effect on human 
atherosclerotic lesions. This study demonstrates that 
reducing LDL concentration to very low levels with the use 
of colestipol and nicotinic acid results in a significant 
benefit to both native coronary arteries and venous bypass 
grafts (Blankenhorn et al. 1987). 
Probucol ( Lorel co) is considered a drug of second 
choice in treatment of primary hypercholesterolemia (Gotto 
1987). The hypocholesterolemic effect of probucol was 
determined in the early 70's in laboratory animals and man 
(Rifkind and Levy 1977). The chemical structure of the drug 
sets it aside from the other hypocholesterolemic agents, 
although it is considered a congener of clofibrate (a 
fibric acid). 
The mechanism of action of probucol in humans is not 
clear. In rabbits, it appears to promote removal of LDL 
chol estero! through a pathway not mediated by the LDL 
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receptor (Steinberg 1986). Probucol increased the 
fractional removal rate of LDL, an action linked to 
increased bile acid excretion (Nestel & Billington 1980). 
Probucol has been demonstrated to be incorporated into LDL 
particles inhibiting the oxidative modification. The 
"antioxidant" property of probucolprevents the LDL from 
being taken up by macrophages which can only internalize 
oxidative modified LDL through its acetyl LDL receptor 
(Carew et al. 1987}. THus even though the LDL concentration 
in bl cod is sti 11 high, the LDL-chol esterol cannot de 
incorporated into the atherosclerotic lesion by the 
macrophage scavenger pathway. The lowering action of 
probucol on HDL levels is profound, and it is opposed to 
the common principles of treatment of hypercholesterolemia 
in which other drugs like cholestyramine and niacin which 
tended to increase serum HDL cholesterol concentration 
(Berget al. 1988). The drug clearly suppresses apoprotein 
AI synthesis which is necessary for HDL formation.' 
Although probucol decreases HDL as well as LDL levels 
by 10 to 30\, respectively, regression of xanthomas and 
improvement of ischemic EKG changes (increased Q-T 
interval), and coronary morphology measured by arterial 
angiography (diminished atherosclerotic progression) is 
induced by probucol administration in spite of HDL 
decreases (Berg et al. 1988). That is, probucol may have 
the ability to prevent the atherogenic process of 
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atherosc1 erotic p1 aque formation, but it sti 11 remains 
unclear whether treatment with probucol effectively 
produces atherosclerotic regression. This study was 
performed in only 16 patients between the ages of 20 and 40 
years of age which is a very small group sample. However, 
studies performed by Wissler and Vesselinovitch (1983) 
suggest that the combined therapy of probucol with 
cholestyramine may actually cause regression in the aortas 
of rhesus monkeys. However, its efficacy and safety still 
remain to be tested by a long term trial (Oliver 1983). 
Thus, for safety reasons, treatment of a 
hypercholesterolemic patient with probucol is not 
recommended unless other means like diet, bile acid binding 
resins,niacin or lovastatin have failed to cause any change 
in LDL cholesterol levels. 
Dujovne et al. reported that probucol and colestipol 
showed a synergistic effect if used concurrently. The 
probucol and colestipol combination reduced mean serum LDL 
levels from 242 ± 51 (SE)mg/dl during the diet and placebo 
to 171 ± 41 mg/dl. 
Clofibrate and its recent congener gemfibrozil, have 
been one of the most widely used drugs for the treatment of 
hyperlipidemia since 1963 (Woolf 1982). Although its 
mechanism of action at the cellular level is not well 
known, the principal effects of clofibrate and other 
fibric acid derivatives, with the exception of probucol, is 
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to increase the rate of metabolism of triglyceride rich 
proteins due to increases in the activity of the 
lipoprotein lipase clearance system (Kesaniemi & Grundy 
1984; Katzung 1987). This mechanism of clofibrate, in turn, 
enhances the rate of intravascular catabolism of VLDL and 
IDL to LDL. It increases the synthesis of VLDL or perhaps 
the protein component of that lipoprotein (Meyers et al. 
1980). The secretion of VLDL from the liver is unaffected 
in hypertriglyceridemic patients and actually appears to be 
increased in normotriglyceridemic subjects. This could 
explain the lack of significant synergism in most patients 
with heterozygous familial hypercholesterolemia treated 
with a combination of bile acid binding resin and 
clofibrate (Katzung 1987). Clofibrate appears to have very 
little effect, if at all, on the plasma LDL cholesterol; 
although it slightly increases HDL cholesterol levels 
(Meyers et al. 1980). 
Many studies have been carried out to evaluate the 
lipid lowering effects of clofibrate. But until 1974 there 
was no clinical end point or data suggesting that 
clofibrate may have some effect on atherosclerosis . Cohn, 
Sakai, and Langston (1975) performed an angiographic study 
in 40 patients in their late forties using clofibrate, 16 
of whom underwent treatment with clofibrate. The study did 
not show any significant effect of clofibrate on the 
coronary arterial wall, but rather observed a significant 
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difference between the placebo and clofibrate groups in the 
degree of coronary disease progressionas measured by 
arteri 1 angiography. These results were 1 imi ted by the 
short duration of the study, crude estimates of change in 
coronary pathology, small numbers of patients and the 
patients' extensive degrees of coronary disease (Cohn, 
Sakai and Langston 1975). 
Experiments with swine performed by Daoud et al . 
(1984) showed that a diet low in cholesterol did not result 
in a decrease in the size of the atherosclerotic lesion, 
but it did prevent their progression. However, the addition 
of clofibrate to such a diet caused regression which 
involved a significant size of the lesion in abdominal 
aortas. 
Erikson et al. (1988) recently demonstrated that the 
use of fenofibrate, a derivative of clofibrate, caused 
regression in 5 out of 31 male patients between the ages of 
35 and 65 years treated with the drug. Although the femoral 
angiography was performed up to three times without any 
complications, the visual analysis of the arteriograms 
revealed considerable inter-observer variation (Erickson et 
al. 1988). This study was limited by the fact that only 31 
patients were receiving the drug and that variations were 
found in the analysis of the computerized angiograms. 
Recent pharmacologic developments for the treatment of 
hypercholesterolemia has led to the discovery of a new type 
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of hypocholesterolemic drug. These drugs are inhibitors of 
the enzyme 3-hydroxy-2-methylglutaryl CoA (HMG-CoA) 
reductase which is the rate limiting step enzyme in the 
conversion of HMG-CoA to cholesterol (Goodman and Gilman 
1985). Lovastatin (Mevacor) is extremely effective in 
lowering serum cholesterol by stimulating the removal of 
LDL-cholesterol from plasma via the LDL receptor mediated 
endocytosis (Prescription insert). Lovastatin has proven to 
be in many studies much more effective in reducing serum 
cholesterol levels than gemfibrozil alone (Tikkanen et al. 
1988). In a comparison study lovastatin proved to be the 
only treatment free of side effects when compared to 
cholestyramine, neomycin and niacin (Hoeg et al. 1987). 
However, there are no published studies thus far that have 
demonstrated any evidence of the effect of HMG-CoA 
reductase inhibitors in the treatment of atherosclerosis. 
However, since this drug is indeed effective in reducing 
LDL-cholesterol levels, it certainly has the potential of 
being a candidate for inducing regression of 
atherosclerosis. 
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Conclusions and Recommendations 
The primary aim in the treatment of atherosclerosis 
has been directed towards diminishing the content of 
cholesterol so as to prevent further lipid deposition in 
atherosclerotic plaques. With the use of animal models and 
arterial angiographies, evidence suggests that reduction of 
serum cholesterol and the anti-atherogenic effect of some 
hypocholesterolemic drugs promotes the regression of 
atherosclerotic lesions. 
Studies which evaluate the effects of a modified diet 
low in cholesterol have demonstrated a beneficial effect in 
arresting the progression of atherosclerotic lesions. 
Animal models have demonstrated that the implementation of 
diets high in fiber and polyunsaturated fat modifies the 
lipid composition of plasma and reduces lipid accumulation 
in the arterial wall (Blankenhorn 1986; Armstrong and Megan 
1972). Decreased deposition of cholesterol in the arterial 
wall results in the enhancement of cholesterol efflux from 
existing arterial lesions and the size of the 
atherosclerotic plaques is reduced. However, the mechanisms 
by which polyunsaturated fat and water soluble and 
insoluble fiber are capable of affecting lipid deposition 
is still unknown. Hypocholesterolemic drugs like 
cholestyramine and clofibrate have not only been effective 
in reducing serum cholesterol, but also have been shown to 
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have a positive effect in the progression and regression of 
atherosclerotic lesions as well. New discoveries in the 
pharmacologic field have led to the development of other 
drugs like mevinolin (Tobert 1987; Grundy and Vega 1985) 
and granulocyte-macrophage colony-stimulating factor (GM-
CSF) (Nimer et al. 1988) which lower serum cholesterol but 
have not yet been proven to cause regression of 
atherosclerotic lesions. 
There is need for further investigation with patients 
and animal models to prove that atherosclerotic regression 
can occur in humans. Correlation between observations of 
atherosclerotic regression in treated animals and clinical 
trials need to be enhanced. Studies with longer use of 
hypocholesterolemic drugs need to be performed in order to 
prove their capability for producing atherosclerotic 
regression. 
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